Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.76 |
| ▸ | TACR1 | P25103 | 16/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | TACR3 | P29371 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30376925 | 1.00 | GPBAR1 (0.76) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL1869259 | 0.96 | GPBAR1 (0.71) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL27643001 | 0.91 | GPBAR1 (0.64) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL337184 | 0.91 | TACR1 (0.74) | GPBAR1TACR1TACR3 | |
| SCHEMBL1870300 | 0.90 | GPBAR1 (0.61) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL1867632 | 0.89 | GPBAR1 (0.69) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL1870080 | 0.89 | GPBAR1 (0.60) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL1872983 | 0.89 | TACR1 (0.61) | GPBAR1TACR1TACR3 | |
| SCHEMBL1876978 | 0.88 | GPBAR1 (0.59) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL5781472 | 0.88 | TACR1 (0.72) | GPBAR1TACR1CYP3A4TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309559-B1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2006-06-07 | — | — | EP | claimed |
| EP-1621195-A2 | The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | claimed |
| EP-1406618-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS WITH PYRIDINIC STRUCTURE FOR THE TREATMENT OF BRAIN, SPINAL OR NERVE INJURY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-14 | — | — | EP | claimed |
| EP-1385577-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | F. Hoffman-la Roche AG (CH) | 2004-02-04 | — | — | EP | claimed |
| EP-1309559-A1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-14 | — | — | EP | claimed |
| US-20030083345-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-01 | — | — | US | claimed |
| WO-2003006016-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS WITH PYRIDINIC STRUCTURE, FOR THE TREATMENT OF BRAIN, SPINAL OR NERVE INJURY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-23 | — | — | WO | claimed |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | claimed |
| WO-2002085458-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | F. HOFFMAN-LA ROCHE AG (CH) | 2002-10-31 | — | — | WO | claimed |
| US-20020040040-A1 | Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors | F. HOFFMAN-LA ROCHE AG (CH) | 2002-04-04 | — | — | US | claimed |
| WO-2002016324-A1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | WO | claimed |
| US-12071421-B2 | Process for the synthesis of substituted chloromethyl dialkylphosphates | HELSINN HEALTHCARE SA (CH) | 2024-08-27 | — | — | US | disclosed |
| US-20220401463-A1 | SUBSTITUTED 4-PHENYL-PYRIDINES | HELSINN HEALTHCARE SA (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220401463-A1 | SUBSTITUTED 4-PHENYL-PYRIDINES | HELSINN HEALTHCARE SA (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220127206-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
| WO-2003006016-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS WITH PYRIDINIC STRUCTURE, FOR THE TREATMENT OF BRAIN, SPINAL OR NERVE INJURY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-23 | — | — | WO | disclosed |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | disclosed |
| WO-2002085458-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | F. HOFFMAN-LA ROCHE AG (CH) | 2002-10-31 | — | — | WO | disclosed |
| US-20020040040-A1 | Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors | F. HOFFMAN-LA ROCHE AG (CH) | 2002-04-04 | — | — | US | disclosed |
| WO-2002016324-A1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127206-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | MGMT, FANCD2, ADAR | GPBAR1 4770/4885TACR1 4580/4885CYP3A4 2632/4885 |
| US-20020040040-A1 | Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors | NPSR1, NTSR1, NTSR2 | GPBAR1 430/4885TACR1 4/4885CYP3A4 1861/4885 |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | KLK3, TACR1, TACR2 | GPBAR1 84/4885TACR1 2/4885CYP3A4 1133/4885 |
| US-20220401463-A1 | SUBSTITUTED 4-PHENYL-PYRIDINES | BDKRB2, BDKRB1, TACR1 | GPBAR1 40/4885TACR1 3/4885CYP3A4 1121/4885 |
| US-20030083345-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | NTRK2, NTSR1, NMUR1 | GPBAR1 333/4885TACR1 9/4885CYP3A4 3268/4885 |
| US-12071421-B2 | Process for the synthesis of substituted chloromethyl dialkylphosphates | BDKRB1, BDKRB2, TK1 | GPBAR1 349/4885TACR1 11/4885CYP3A4 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.